Serotonergic drug
pharmacologyAny substance that raises serotonin signalling, whether by releasing it, blocking its reuptake, slowing its breakdown, or acting directly at its receptors. The category gathers compounds from very different classes — antidepressants, opioids, stimulants, psychedelics — which is why serotonin syndrome is discussed at the level of the category rather than of individual drugs.
A serotonergic drug is any substance that alters serotonin (5-HT) activity in the nervous system — either by increasing the amount available in the synapse, or by activating its receptors directly. The term describes a mechanism, not a drug class: a molecule can be serotonergic as its primary action or as an incidental property alongside other effects.
Because serotonin regulates mood, sleep, appetite, arousal, and perception, the category spans an unusually wide range of substances. Antidepressants, stimulants, entactogens, classical psychedelics, and some opioids are all serotonergic, even though their subjective effects and clinical uses differ sharply.
How it works · its role
Four mechanisms produce serotonergic activity. Release: the drug causes neurons to pump serotonin into the synapse rapidly and in large amounts. Reuptake inhibition: the drug blocks the serotonin transporter (SERT), slowing clearance and letting serotonin linger. Enzymatic inhibition: the drug blocks monoamine oxidase (MAO), which normally breaks serotonin down, raising its sustained baseline level. Receptor agonism: the drug binds directly to serotonin receptor subtypes — most often 5-HT₂A or 5-HT₁A — and activates them without requiring endogenous serotonin.
A single substance can act through more than one of these routes simultaneously. When two serotonergic drugs reach the same pathway by different mechanisms, their combined effect on signalling can multiply rather than simply add.
Relevance to substances & effects
SSRIs and SNRIs act by blocking SERT, producing gradual mood stabilisation that builds over weeks; their serotonergic effects are subtle at therapeutic doses. MDMA and related entactogens force rapid, large-scale serotonin release, producing the characteristic emotional warmth, openness, and sensory enhancement of that class.
Classical psychedelics such as psilocin and LSD are serotonergic primarily through direct 5-HT₂A agonism — which drives their perceptual and cognitive changes rather than the warmth associated with release. Some opioids, including tramadol and meperidine, carry meaningful serotonergic activity alongside their opioid effects, raising interaction risk even when their opioid properties alone would not.
Because the mechanisms stack, combining drugs from this category — particularly pairing a releaser or reuptake inhibitor with an MAOI — can push serotonin signalling to dangerous levels. This is the pharmacological basis of serotonin syndrome, and it is why serotonergic combinations are flagged as a unified risk class in the interaction layer of the encyclopedia, rather than substance by substance.
AI-generated · not yet verified by a human reviewer
Harm-reduction reference — not medical advice.